Mind the continuation gap

A granted patent is where most companies stop. It's where the strategic leverage actually starts.

On the London Underground, a recorded voice reminds you to mind the gap, the space between the train and the platform edge, the place you fall if you're not paying attention. Patents have a gap of their own. It isn't a defect in the drafting. It's a problem of timing, and most companies never notice it until they've already fallen in.

Every patent is written partly blind

When you file a patent application, you're describing your invention before the market has told you what actually matters. You don't yet know which feature a competitor will copy, which claim wording a rival will design around, or which corner of your technology turns out to be the valuable one. You're aiming at a target that hasn't fully appeared.

That's the gap: the distance between the claims you can write on the day you file and the claims you would write if you could see two or three years down the track. At filing, you're guessing, intelligently, but guessing, about where the value and the infringement will land.

A continuation is how you keep from falling into that gap.

What a continuation actually is

When a patent application is allowed, you don't have to treat that as the end. Before it issues, you can file a continuation: a child application that carries forward the exact same disclosure as the original ("parent") application, while pursuing different or additional claims. Because it claims priority to the parent, it keeps your original filing date. What it buys you is the ability to write new claims, later, informed by everything you've learned since you first filed, all still anchored to that early priority date.

A few related tools live in the same family, and it's worth knowing the difference:

• Continuation: same disclosure as the parent, new claims. The workhorse of the strategy described here.
• Divisional: used when the examiner says your application covers more than one distinct invention (a "restriction requirement"); you split the extra invention into its own application, again keeping the original date.
• Continuation-in-part (CIP): adds new material to the original disclosure. Useful when the technology has genuinely evolved, but the new material only gets the later filing date, so it's a different tool with different tradeoffs.

The strategy in this article is mostly about ordinary continuations: keeping a live application pending off a disclosure you've already filed, so you retain the right to write fresh claims against it.

Why keeping one alive changes the game

Holding a continuation open turns a single filing into a standing option. Three concrete payoffs:

You can aim at what competitors actually built

Suppose a rival ships a product that plainly reads on your original disclosure but carefully sidesteps the specific claims that issued. With a live continuation, you can draft new claims that read squarely on what they're doing, using language you now know to use, still supported by your original specification and still carrying your original filing date. Without a pending continuation, that door is closed: you're limited to the claims you happened to write before the competitor existed.

You can follow the market

The feature everyone thought was central at filing turns out to be a footnote; the throwaway detail becomes the whole product. Markets do this constantly. A continuation lets you re-point your claims at where the value actually landed, rather than being frozen with the emphasis you guessed at on day one, provided your original disclosure described that detail in enough depth to support claims to it. (Which is exactly why a thorough original specification matters so much; you can only later claim what you adequately disclosed at the start.)

You keep optionality open

As long as one continuation stays pending, the family isn't closed. You retain the ability to keep writing claims against a moving competitive landscape for as long as you maintain the chain. Each time one application is about to issue, you can file another continuation before it does, keeping the option alive. It's a modest ongoing cost in exchange for years of strategic flexibility.

The unmined disclosure most companies leave behind

Here's the part that surprises people. A well-drafted patent application usually discloses far more than its issued claims actually cover. The specification might describe five embodiments; the granted claims might practically protect one. The rest, real, still-protectable subject matter you already paid to describe, just sits in the published document, unclaimed.

Most companies never come back for it. They file, they get a grant, they frame the certificate, and they let the family go quiet, closing the door right when it would start to pay off. A continuation strategy is, in part, the discipline of mining your own disclosures: systematically reviewing what you've already filed for valuable subject matter you never claimed, and pursuing it while the priority date still protects you. Because the disclosure already exists, this is often some of the highest-return patenting a company can do.

When it's worth it, and when it isn't

Continuations aren't free, and keeping one pending forever isn't automatically wise. Each pending application carries its own government fees and attorney cost when you actually write and prosecute new claims, and there are doctrines (such as obviousness-type double patenting, and defenses like prosecution laches for extreme, unjustified delay) that constrain how far the strategy can be pushed. The point is not to keep everything open indefinitely; it's to keep the right families open, deliberately.

Continuations tend to be most worth it when: the technology sits in a fast-moving, competitive space; your original disclosure was rich enough to support claims you haven't written yet; the asset is commercially important enough to defend; or you can already see competitors circling. They're less compelling for peripheral inventions, thin disclosures, or technology that's aging out of relevance. Deciding which families justify a live continuation is itself a strategic judgment, the same "what's worth protecting" discipline applied to your existing portfolio rather than to new inventions.

Mind the continuation gap

The first filing is a bet placed before the race starts. A continuation is the bet you get to place after you've watched a few laps, with the same early odds. Treated that way, a granted patent isn't the finish line; it's the point where the real strategic leverage begins.

So when a patent issues, don't reflexively let the family close. Look at what the disclosure could still support, look at what your competitors are doing, and decide, deliberately, whether to keep a continuation alive. Mind the gap.